Most major pharmaceutical companies have reported results for 2016 during the last few weeks, providing the opportunity to update our industry statistics. For an industry that requires a long investment cycle, decisions made many years ago have consequences on current financial performance. Being able to look at performance over 20 years highlights how strategic decisions have panned out.

01 Mar 2017
Hardman & Co Monthly: March 2017
Abzena (ABZA:LON), 0 | Allergy Therapeutics plc (AGY:LON), 7.9 | Arbuthnot Banking Group PLC (ARBB:LON), 968 | Avacta Group PLC (AVCT:LON), 32.0 | Burford Capital Limited (BUR:LON), 1,052 | Cambridge Cognition Holdings Plc (COG:LON), 32.5 | City of London Investment Group PLC (CLIG:LON), 358 | TheraCryf PLC (TCF:LON), 0.3 | Genedrive Plc (GDR:LON), 1.4 | Murgitroyd Group (MUR:LON), 0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.8 | PPHE Hotel Group Limited (PPH:LON), 1,599 | Primary Health Properties PLC (PHP:LON), 96.0 | R.E.A. Holdings plc (RE:LON), 83.5 | Scancell Holdings Plc (SCLP:LON), 10.2 | Sinclair Pharma (SPH:LON), 0 | Tissue Regenix Group plc (TRX:LON), 26.5 | Titon Holdings Plc (TON:LON), 90.0 | Oxford BioMedica plc (OXB:LON), 357 | ValiRx PLC (VAL:LON), 0.6 | Verona Pharma plc Sponsored ADR (VRNA:NAS), 0

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Hardman & Co Monthly: March 2017
Abzena (ABZA:LON), 0 | Allergy Therapeutics plc (AGY:LON), 7.9 | Arbuthnot Banking Group PLC (ARBB:LON), 968 | Avacta Group PLC (AVCT:LON), 32.0 | Burford Capital Limited (BUR:LON), 1,052 | Cambridge Cognition Holdings Plc (COG:LON), 32.5 | City of London Investment Group PLC (CLIG:LON), 358 | TheraCryf PLC (TCF:LON), 0.3 | Genedrive Plc (GDR:LON), 1.4 | Murgitroyd Group (MUR:LON), 0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.8 | PPHE Hotel Group Limited (PPH:LON), 1,599 | Primary Health Properties PLC (PHP:LON), 96.0 | R.E.A. Holdings plc (RE:LON), 83.5 | Scancell Holdings Plc (SCLP:LON), 10.2 | Sinclair Pharma (SPH:LON), 0 | Tissue Regenix Group plc (TRX:LON), 26.5 | Titon Holdings Plc (TON:LON), 90.0 | Oxford BioMedica plc (OXB:LON), 357 | ValiRx PLC (VAL:LON), 0.6 | Verona Pharma plc Sponsored ADR (VRNA:NAS), 0
- Published:
01 Mar 2017 -
Author:
Martin Hall -
Pages:
40 -
Most major pharmaceutical companies have reported results for 2016 during the last few weeks, providing the opportunity to update our industry statistics. For an industry that requires a long investment cycle, decisions made many years ago have consequences on current financial performance. Being able to look at performance over 20 years highlights how strategic decisions have panned out.